Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06083402 · ClinicalTrials.gov registry record · NA
Efficacy of a Dietary Supplement on Parameters of Skin Aging in Men and Women
A NA study of Skin Aging, sponsored by Natals, Inc. dba Ritual.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT06083402: Completed NA study of Skin Aging, sponsored by Natals, Inc. dba Ritual.
NCT06083402 is a NA study of Skin Aging that has completed, run by Natals, Inc. dba Ritual. The registered enrollment target is 63 participants, roughly in line with the 68-participant average among 9 other Skin Aging trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06083402, a NA study of Skin Aging, has completed, sponsored by Natals, Inc. dba Ritual.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
As the body ages, the skin experiences natural changes in structure and composition. These changes may manifest visibly as increased skin dryness, wrinkling, and a loss of firmness/elasticity. In this double-blind, randomized, placebo-controlled trial, the investigators will recruit healthy men and women with mild to moderate signs of skin aging and randomly assign them to either receive a HyaCera™ or placebo for 12 weeks. The investigators will perform a series of objective and subjective measurements to assess changes in skin condition. The investigators hypothesize that consumption of HyaCera™ leads to improvements in the general condition of the skin including skin hydration, crow's feet wrinkling, and other skin aging parameters.
Primary Outcome
Degree of crow's feet wrinkling will be measured via Visioscan®
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT HyaCera™
Study Locations (1)
New Jersey
- Princeton Consumer Research - Raritan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2023-10-06 |
| Phase | NA |
What the finished NCT06083402 record still lists
NCT06083402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 68-participant average among 9 other Skin Aging trials with a reported enrollment target.
The record links to 1 condition, with Skin Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06083402 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06083402 about?
NCT06083402 is a clinical study titled "Efficacy of a Dietary Supplement on Parameters of Skin Aging in Men and Women". As the body ages, the skin experiences natural changes in structure and composition. These changes may manifest visibly as increased skin dryness, wrinkling, and a loss of firmness/elasticity. In this double-blind, randomized, placebo-controlled trial, the investigators will recruit healthy men and ...
What is the current status of trial NCT06083402?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2023-06-12. Estimated completion is 2023-10-06.
What conditions does trial NCT06083402 study?
This clinical trial studies the following conditions: Skin Aging.
What interventions are being tested in trial NCT06083402?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), HyaCera™ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06083402?
This trial is sponsored by Natals, Inc. dba Ritual, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06083402 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06083402's enrollment target sits among peer trials
63 3rd of 9 higher than 7 of 9 other Skin Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging
ACTIVE NOT RECRUITING · NA
-
A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging, by Comparing to a Placebo
ACTIVE NOT RECRUITING · NA
-
Clinical Trial to Evaluate the Efficacy of Skin Products to Improve Skin Quality and Health
COMPLETED · NA
-
Thermage CPT for Treatment of Facial and Neck Laxity
COMPLETED · NA
-
Relationship of Skin Related SNP to Topical Skin Care Product
COMPLETED · NA
-
A Proof of Concept Study to Evaluate the Efficacy and Tolerability of Skinpen on Male and Female Subjects' Dorsal Hands as a Treatment of Hand Aging
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI